Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0142-0000-0002 induction trial in moderately to severely active Crohn's disease
2010-020836-21Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing NNC0142-0000-0002 with Placebo (2 arms). Primary endpoint: Change in Crohn's disease activity index. Started Sep 2010; status: completed.
02
Drugs
NNC0142-0000-0002
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2010-020836-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020836-21.